JP2024538117A5 - - Google Patents
Info
- Publication number
- JP2024538117A5 JP2024538117A5 JP2024522406A JP2024522406A JP2024538117A5 JP 2024538117 A5 JP2024538117 A5 JP 2024538117A5 JP 2024522406 A JP2024522406 A JP 2024522406A JP 2024522406 A JP2024522406 A JP 2024522406A JP 2024538117 A5 JP2024538117 A5 JP 2024538117A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163262466P | 2021-10-13 | 2021-10-13 | |
| US63/262,466 | 2021-10-13 | ||
| PCT/US2022/046291 WO2023064282A1 (en) | 2021-10-13 | 2022-10-11 | Combinations of wee 1 inhibitors and anti-cd47 antibodies. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538117A JP2024538117A (ja) | 2024-10-18 |
| JP2024538117A5 true JP2024538117A5 (https=) | 2025-10-22 |
Family
ID=85987727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522406A Pending JP2024538117A (ja) | 2021-10-13 | 2022-10-11 | Ｗｅｅ１阻害剤と抗ｃｄ４７抗体との組み合わせ。 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240261295A1 (https=) |
| EP (1) | EP4415721A4 (https=) |
| JP (1) | JP2024538117A (https=) |
| CN (1) | CN118139625A (https=) |
| TW (1) | TW202320758A (https=) |
| WO (1) | WO2023064282A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2026082160A1 (zh) * | 2024-10-18 | 2026-04-23 | 上海瑛派药业有限公司 | Wee1蛋白降解剂及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014244083B2 (en) * | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| US20220184087A1 (en) * | 2019-03-28 | 2022-06-16 | The Penn State Research Foundation | Methods and compositions relating to treatment of cancer |
| ES2973832T3 (es) * | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
-
2022
- 2022-10-11 JP JP2024522406A patent/JP2024538117A/ja active Pending
- 2022-10-11 EP EP22881660.9A patent/EP4415721A4/en active Pending
- 2022-10-11 CN CN202280064571.4A patent/CN118139625A/zh active Pending
- 2022-10-11 WO PCT/US2022/046291 patent/WO2023064282A1/en not_active Ceased
- 2022-10-12 TW TW111138638A patent/TW202320758A/zh unknown
-
2024
- 2024-04-12 US US18/634,055 patent/US20240261295A1/en active Pending